Autoimmune component in the etiology of sarcoidosis
A. A. Starshinova,
A. M. Malkova,
Yu. S. Zinchenko,
N. Yu. Basantsova,
D. A. Kudlay,
P. K. Yablonskiy https://doi.org/10.21292/2075-1230-2020-98-5-54-62
Abstract
The article presents a review of 60 publications from international and Russian databases (PubMed, Web of Science, and Elsevier) from 1960 to 2018 with the keywords "sarcoidosis," "autoimmune reactions," "antibodies," and "HLA-genotype" characterizing sarcoidosis as an autoimmune disease. The information is divided into sections: the role of triggers, clinical manifestations and combination with autoimmune diseases, immunogenetic predisposition, features of cellular immune response, humoral immune response, and immunosuppressive therapy.
About the Authors
A. A. Starshinova
Almazov National Medical Research Center
Russian Federation
Anna A. Starshinova Doctor of Medical Sciences, Head of Research Directorate
Russian Federation
Anna A. Starshinova Doctor of Medical Sciences, Head of Research Directorate
A. M. Malkova
St. Petersburg University
Russian Federation
Anna M. Malkova Junior Researcher of Autoimmunity Mosaic Laboratory
Russian Federation
Anna M. Malkova Junior Researcher of Autoimmunity Mosaic Laboratory
Yu. S. Zinchenko
St. Petersburg Research Institute of Phthisiopulmonology
Russian Federation
Yulia S. Zinchenko Pulmonologist, Researcher
Russian Federation
Yulia S. Zinchenko Pulmonologist, Researcher
N. Yu. Basantsova
St. Petersburg University; St. Petersburg Research Institute of Phthisiopulmonology
Russian Federation
Natalya Yu. Basantsova Neurologist, Researcher
Russian Federation
Natalya Yu. Basantsova Neurologist, Researcher
D. A. Kudlay
NRC Institute of Immunology FMBA of Russia
Russian Federation
Dmitry A. Kudlay Doctor of Medical Sciences, Leading Researcher of Personalized Medicine and Molecular Immunology Laboratory no.71
Russian Federation
Dmitry A. Kudlay Doctor of Medical Sciences, Leading Researcher of Personalized Medicine and Molecular Immunology Laboratory no.71
P. K. Yablonskiy
St. Petersburg University; St. Petersburg Research Institute of Phthisiopulmonology
Russian Federation
Petr K. Yablonskiy Director
Russian Federation
Petr K. Yablonskiy Director
References
1. Vizel А.А., Vizel I.Yu. Leflunomide as a potential second-line drug in the treatment of sarcoidosis. Tuberculosis and Lung Diseases, 2019, vol. 97, no. 8, pp. 52-58. (In Russ.)
2. Ershov G.А., Churilov L.P. About potential autoimmune nature of sarcoidosis: which autologous antigens are involved and why? Klin. Patofiziologiya, 2017, vol. 3, pp. 77-82. (In Russ.)
3. Zinchenko Yu.S., Basantsova N.Yu., Starshinova А.А., Gilburd B., Yablonskiy P.K. Autoimmune/pro-inflammatory syndrome induced by adjuvants and sarcoidosis. Meditsinsky Alyans, 2019, no. 3, pp. 16-21. (In Russ.)
4. Zinchenko Yu.S., Starshinova А.А., Filatov M.V., Istomina E.V., Burdakov V.S., Denisova N.V., Landa S.B., Burdakov V.S., Stepanenko T.А., Yablonskiy P.K. Autoimmune nature of sarcoidosis: the identification of specific immune complexes in patients with respiratory sarcoidosis. Meditsinskaya Immunologiya, 2019, vol. 3, pp. 479-486. (In Russ.)
5. Ilkovich M.M., eds., Interstitsialnye i orfannye zabolevaniya legkikh. [Interstitial and orphan lung diseases]. Moscow, GEOTAR-Media Publ., 2016, pp. 560.
6. Kudryavtsev I.V., Lazareva N.M., Baranova O.P., Serebryakova M.K., Ses T.P., Ilkovich M.M., Totolyan А.А. Features of CD57 expression by cytotoxic T-lymphocytes in sarcoidosis. Rossiyskiy Immunologicheskiy Journal, 2018, vol. 12, no. 21, pp. 329-334. (In Russ.)
7. Lazareva N.M., Kudryavtsev I.V., Baranova O.P., Serebryakova M.K., Ses T.P., Ilkovich M.M., Totolyan А.А. Subpopulation of cytotoxic T-lymphocytes of peripheral blood in sarcoidosis. Rossiyskiy Immunologicheskiy Journal, 2018, vol. 12, no. 21, pp. 348-353. (In Russ.)
8. Ahmadzai H., Cameron B., Chui J., Lloyd A., Wakefield D., Thomas P. Peripheral blood responses to specific antigens and CD28 in sarcoidosis. J. Respir. Med., 2012, vol. 106, no. 5, pp. 701-709. https://doi.org/10.1371/journal.pone.0154716.
9. Ang S.C., Moscovic E.A. Cross-reactive and species specific mycobacterium tuberculosis antigens in the immunoprofile of Schaumann bodies: a major clue to the etiology of sarcoidosis. J. Histol. Histopathol., 1996, vol. 11, no. 1, pp. 125-134.
10. Arango M., Perricone C., Kivity S., Cipriano E., Ceccarelli F., Valesini G., Shoenfeld Y. HLA-DRB1 the notorious gene in the mosaic of autoimmunity. J. Immunol. Res., 2017, vol. 65, no. 1, pp. 82-98. doi: 10.1007/s12026-016-8817-7.
11. Armbruster C., Dekan G., Hovorka A. Granulomatous pneumonitis and mediastinal lymphadenopathydue to photocopier toner dust. Lancet, 1996, vol. 348, no. 9028, pp. 690, doi: 10.1016/S0140-6736(05)65119-7.
12. Balk E.M., Earley A., Avendano E.A., Raman G. Long-termhealth outcomes in women with silicone gel breast implants: a systematic review. Ann. Intern. Med., 2016, vol. 164, pp. 164-175. doi:10.7326/M15-1169.
13. Baughman R.P., Lower E.E. Leflunomide for chronic sarcoidosis. Sarcoidosis Vasc. Dif. Lung Dis., 2004, vol. 21, no. 1, pp. 43-48.
14. Belhomme N., Jouneau S., Bouzillé G., Decaux O., Lederlin M., Guillot S., Perlat A., Jégo P. Role of serum immunoglobulins for predicting sarcoidosis outcome: A cohort study. PLoS One, 2018, vol. 13, no. 4, e0193122. doi: 10.1371/journal.pone.0193122.
15. Bindoli S., Dagan A., Torres-Ruiz J.J., Perricone C., Bizjak M., Doria A., Shoenfeld Y. sarcoidosis and autoimmunity: from genetic background to environmental factors. Isr. Med. Assoc. J., 2016, vol. 18, no. 3-4, pp. 197-202.
16. Bowers B., Hasni S., Gruber B.L. Sarcoidosis in world trade center rescue workers presenting with rheumatologic manifestations. J. Clin. Rheumatol., 2010, vol. 16, no. 1, pp. 26-27.
17. Cain H., Kraus B. Immunofluorescence microscopic demonstration of vimentin filaments in asteroid bodies of sarcoidosis. A comparison with electron microscopic findings. J. Virchows Arch B Cell Pathol. Incl. Mol. Pathol., 1983, vol. 42, no. 2, pp. 213-226. doi: 10.1007/bf02890384.
18. Cohen Tervaert J.W., Colaris M.J., van der Hulst R.R. Silicone breast implants and autoimmune rheumatic diseases: myth or reality. Curr. Opin. Rheumatol., 2017, vol. 29, pp. 348-354. doi: 10.1097/BOR.0000000000000391.
19. Darlington P., Tallstedt L., Padyukov L., Kockum I., Cederlund K., Eklund A. et al. HLA-DRB1 alleles and symptoms associated with Рeerfordt’s syndrome in sarcoidosis. J. Eur. Respire, 2011, vol. 38, pp. 1151-1157. doi: 10.1183/09031936.00025011.
20. Denic A., Wootla B., Rodriguez M. CD8(+) T cells in multiple sclerosis. Expert. Opin. Ther. Targets, 2013, vol. 17, no. 9, pp. 1053-1066. doi: 10.1517/14728222.2013.815726.
21. Drake W.P., Dhason M.S., Nadaf M., Shepherd B.E., Vadivelu S., Hajizadeh R., Newman L.S., Kalams S.A. Cellular recognition of mycobacterium tuberculosis ESAT-6 and KATG peptides in systemic sarcoidosis. J. Infectimmun., 2007, vol. 75, pp. 527-530 doi: 10.1007/s10875-009-9311-y.
22. Dua A., Manadan A. Images in clinical medicine. Heerfordt’s syndrome, or uveoparotid fever. N. Engl. J. Med., 2013, vol. 369, no. 5, pp. 458. doi:10.1056/NEJMicm1303454.
23. Ewers U., Nowak D. Gesundheitsschäden und Erkrankungen durch Emissionen aus Laserdruckern und Kopiergeräten? Gefahrstoffe. Reinhalt. Luft., 2006, vol. 66, pp. 203-210.
24. Fagan E.A., Moore-Gillon J.C., Turner-Warwick M. Multiorgan granulomas and mitochondrial antibodies. J. Med., 1983, vol. 308, pp. 572-575. doi: 10.1056/NEJM198303103081006.
25. Farhat S.C., Silva C.A., Orione M.A., Campos L.M., Sallum A.M., Braga A.L. Air pollution in autoimmune rheumatic diseases: a review. Autoimmun. Rev., 2011, vol. 11, no. 1, pp. 14-21. doi: 10.1016/j.autrev.2011.06.008.
26. Fingerlin T.E., Hamzeh N., Maier L.A. Genetics of sarcoidosis. J. Clin. Chest Med., 2015, vol. 36, pp. 569-584. doi: 10.1016/j.ccm.2015.08.002.
27. Georas S.N., Chapman T.J., Crouser E.D. Sarcoidosis and T-helper cells. Th1, Th17, or Th17.1? Am. J. Respir. Crit. Care Med., 2016, vol. 193, no. 11, pp. 1198-200.
28. Hu Y., Yibrehu B., Zabini D., Kuebler W.M. Animal models of sarcoidosis. J. Cell Tissue Res., 2017, vol. 367, no. 3, pp. 651-661 DOI: 10.1007/s00441-016-2526-3.
29. Huang H., Lu Z., Jiang C., Liu J., Wang Y., Xu Z. Imbalance between Th17 and regulatory T-cells in sarcoidosis. J. Mol. Sci., 2013, vol. 14, no. 11, pp. 21463-21473. doi:10.3390/ijms141121463.
30. Kamphuis L.S., van Zelm M.C., Lam K.H., Rimmelzwaan G.F., Baarsma G.S., Dik W.A., Thio H.B., van Daele P.L., van Velthoven M.E., Batstra M.R., van Hagen P.M., van Laar J.A. Perigranuloma localization and abnormal maturation of B cells: emerging key players in sarcoidosis? Am. J. Respir. Crit. Care Med., 2013, vol. 187, no. 4, pp. 406-416. doi: 10.1164/rccm.201206-1024OC.
31. Katchar K., Soderstrom K., Wahlstrom J., Eklund A., Grunewald J. Characterization of natural killer cells and CD56+ T-cells in sarcoidosis patients. Eur. Respir. J., 2005, vol. 26, no. 1, pp. 77-85. doi: 10.1183/09031936.05.00030805.
32. Kobak S. Sarcoidosis: a rheumatologist’s perspective. J. Ther. Adv. Musculoskel. Dis., 2015, vol. 7, no. 5, pp. 196-205. doi:10.1177/1759720X15591310.
33. Kobak S., Yilmaz H., Sever F., Duran A., Sen N. Anti-cyclic citrullinated peptide antibodies in patients with sarcoidosis. J. Vasc. Diffuse Lung Dis., 2014, vol. 31, no. 3, pp. 206-210.
34. Kobak S., Yilmaz H., Sever F., Duran A., Sen N., Karaarslan A. The prevalence of antinuclear antibodies in patients with sarcoidosis. Autoimmune Dis., 2014:351852. doi: 10.1155/2014/351852.
35. Levin A.M., Iannuzzi M.C., Montgomery C.G., Trudeau S., Datta I., McKeigue P. Association of ANXA11 genetic variation with sarcoidosis in African Americans and European Americans. Genes Immun., 2013, vol. 4, pp. 13-18.
36. Maddrey W.C., Johns C.J., Boitnott J.K., Iber F.L. Sarcoidosis and chronic hepatic disease: a clinical and pathological study of 20 patients. J. Medicine., 1970, vol. 49, pp. 375-395. doi: 10.1097/00005792-197009000-00002.
37. Miro-Mur F., Hindie M., Kandhaya-Pillai R., Tobajas V., Schwartz S.Jr., Alijotas-Reig J. Medical-grade silicone induces release of proinflammatory cytokines in peripheral blood mononuclear cells without activating T cells. J. Biomed. Mater. Res. B Appl. Biomater., 2009, vol. 90, no. 2, pp. 510-520. doi: 10.1002/jbm.b.31312.
38. Musaelyan A., Lapin S., Nazarov V., Tkachenko O., Gilburd B., Mazing A., Mikhailova L., Shoenfeld Y. Vimentin as antigenic target in autoimmunity: a comprehensive review. J. Autoimmun. Rev., 2018, vol. 17, no. 9, pp. 926-934. doi: 10.1016/j.autrev.2018.04.004.
39. Nanke Y., Kobashigawa T., Yago T., Kawamoto M., Yamanaka H., Kotake S. Detection of IFN-γ+IL-17+ cells in salivary glands of patients with Sjögren's syndrome and Mikulicz's disease: Potential role of Th17•Th1 in the pathogenesis of autoimmune diseases. Nihon Rinsho Meneki Gakkai Kaishi, 2016, vol. 39, no. 5, pp. 473-477. doi: 10.2177/jsci.39.473
40. Nistala K., Adams S., Cambrook H., Ursu S., Olivito B., de Jager W., Evans J.G., Cimaz R., Bajaj-Elliott M., Wedderburn L.R. Th17 plasticity in human autoimmune arthritis is driven by the inflammatory environment. Proc. Natl. Acad. Sci., USA, 2010, vol. 107, no. 33, pp. 14751-14756. doi: 10.1073/pnas.1003852107.
41. Petrelli A., van Wijk F. CD8(+) T cells in human autoimmune arthritis: the unusual suspects. Nat. Rev. Rheumatol., 2016, vol. 12, no. 7, pp. 421-428. doi: 10.1038/nrrheum.2016.74.
42. Ping W., Song G.Zh. Regulatory T cells and B cells: implication on autoimmune diseases. Int. J. Clin. Exp. Pathol., 2013, vol. 6, no. 12, pp. 2668-2674.
43. Prasse A., Georges C.G., Biller H., Hamm H., Matthys H., Luttmann W., Virchow J.C.Jr. Th1 cytokine pattern in sarcoidosis is expressed by bronchoalveolar CD4+ and CD8+ T cells. Clin. Exp. Immunol., 2000, vol. 122, no. 2, pp. 241-248. doi: 10.1046/j.1365-2249.2000.01365.x.
44. Rigby M.R., Ehlers M.R. Targeted immune interventions for type 1 diabetes: not as easy as it looks!. Curr. Opin. Endocrinol. Diabetes Obes., 2014, vol. 21, no. 4, pp. 271-278. doi: 10.1097/MED.0000000000000075.
45. Rose N.R., Bona C. Defining criteria for autoimmune diseases (witebsky's postulates revisited). J. Immunol. Today, 1993, vol. 14, pp. 426-430.
46. Rossman M.D., Thompson B., Frederick M., Iannuzzi M.C., Rybicki B.A., Pander J.P. HLA and environmental interactions in sarcoidosis. J. Sarcoidosis. Vasc. Diffuse Lung Dis., 2008, vol. 25, pp. 125-132.
47. Rossman M.D., Thompson B., Frederick M., Maliarik M., Iannuzzi M.C., Rybicki B.A. HLA-DRB1*1101: a significant risk factor for sarcoidosis in blacks and whites. J. Hum. Genet., 2003, vol. 73, pp. 720-735. doi: 10.1086/378097.
48. Sahoo D.H., Bandyopadhyay D., Xu M., Pearson K., Parambil J.G., Lazar C.A., Chapman J.T., Culver D.A. Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis. Eur. Respir. J., 2011, vol. 38, no. 5, pp. 1145-1150. doi: 10.1183/09031936.00195010.
49. Sakthivela P., Brudera B. Mechanism of granuloma formation in sarcoidosis. Curr. Opin. Hematol., 2017, vol. 24, no. 1, pp. 59-65. doi: 10.1097/MOH.0000000000000301.
50. Santiago T., Santiago M., Rovisco J., Ferreira J., Duarte C., Malcata A., Da Silva J. Coexisting primary Sjögren’s syndrome and sarcoidosis: coincidence, mutually exclusive conditions or syndrome? J. Rheumatology International., 2014, vol. 34, no. 11, pp. 1619-1622. doi: 10.1007/s00296-014-3024-0.
51. Shoenfeld Y., Agmon-levin N. ASIA ‒ autoimmune/inflammatory syndrome induced by adjuvants. J. Autoimmun., 2011, vol. 36, pp. 4-8. doi: 10.1016/j.jaut.2010.07.003.
52. Soto-Gomez N., Peters J.I., Nambiar A.M. Diagnosis and management of sarcoidosis. J. Am. Family Physician, 2015, vol. 93, pp. 840-850. https://www.aafp.org/afp/2016/0515/p840.html.
53. Stanca C.M., Fiel I.M., Allina J., Caracta C.F., Odin J.A. Liver failure in an antimitochondrial antibody-positive patient with sarcoidosis: primary biliary cirrhosis or hepatic sarcoidosis? J. Semin. Liver Dis., 2005, vol. 25, no. 3, pp. 364-370. doi: 10.1055/s-2005-916327.
54. Vitali C., Bombardieri S., Jonsson R. et al. Classification criteria for Sjogren’s syndrome: a revised version of the european criteria proposed by the american-european consensus group. J. Ann. Rheum Dis., 2002, vol. 61, no. 6, pp. 554-558. doi: 10.1136/ard.61.6.554.
55. Wahlström J., Dengjel J., Persson B., Duyar H., Rammensee H., Stevanovic´ S., Eklund A., Weissert R., Grunewald J. Identification of HLA‒DR-bound peptides presented by human bronchoalveolar lavage cells in sarcoidosis. J. Clin. Invest., 2007, vol. 117, pp. 3576-3582. doi: 10.1172/JCI32401.
56. Wahlström J., Dengjel J., Winqvist O., Targoff I., Persson B., Duyar H., Rammensee H.G., Eklund A., Weissert R., Grunewald J. Autoimmune T cell responses to antigenic peptides presented by bronchoalveolar lavage cell HLA-DR molecules in sarcoidosis. J. Clin. Immunol., 2009, vol. 133, no. 3, pp. 353-363. doi: 10.1016/j.clim.2009.08.008.
57. Watad A., Rosenberg V., Tiosano S. et al. Silicone breast implants and the risk of autoimmune diseases: real world analysis. Ann. Rheum. Dis., 2018, vol. 77, pp. 1191-1192. doi: 10.1093/ije/dyy217.
58. Wesemann D.R., Costenbader K.H., Coblyn J.S. Co-existing sarcoidosis, systemic lupus erythematosus and the antiphospholipid antibody syndrome case reports and discussion from the brigham and women’s hospital lupus center. J. Lupus., 2009, vol. 18, pp. 202-205. doi: 10.1177/0961203308100483.
59. Wu J.J., Schiff K.R. Sarcoidosis. J. Fam. Physician., 2004, vol. 70, no. 2, pp. 312-322.
60. Zolotykh V.G., Kim А.Y., Shoenfeld Y., Churilov L.P. Galactorrhea following silicone breast implant placement. Israel Med. Association J., vol. 21, no. 8, pp. 523,
Review
For citations:
Starshinova A.A., Malkova A.M., Zinchenko Yu.S., Basantsova N.Yu., Kudlay D.A., Yablonskiy P.K. Autoimmune component in the etiology of sarcoidosis. Tuberculosis and Lung Diseases. 2020;98(5):54-62. (In Russ.) https://doi.org/10.21292/2075-1230-2020-98-5-54-62
Views:
1110
Email this article 